Irina Vladimirovna Kolyadina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina Vladimirovna Kolyadina has a total of 428 co-authors. Here are the top co-authors by number of shared publications:
- Irina Vladimirovna Poddubnaya
Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993
10 shared publications - Valery Vitalievich Rodionov
V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
10 shared publications - Vlada V. Kometova
V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
9 shared publications - Yuriy V. Bikeev
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov of the Ministry of Healthcare of the Russian Federation
8 shared publications - Александр Валерьевич Султанбаев
Bashkir State Medical University; Republican Clinical Oncology Dispensary
8 shared publications Колядина Ирина Владимировна
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России; ФГАОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
7 shared publications
Latest Publications
- 10 August 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (4)
Ribociclib-based combination endocrine therapy in elderly and frail patients: key issues of efficacy, safety, and drug interactions requiring the attention of an oncologist
This review presents the findings of the most consequential large-scale randomized controlled trials and real-world practice studies on combination endocrine therapy with ribociclib in elderly patients with advanced HR-positive, HER2-negative breast cancer. Phase 3 and 3b randomized clinical trials (MONALEESA-2, MONALEESA-3, and CompLEEment-1) have consistently demonstrated that endocrine therapy combined with ribociclib confers a significant advantage over endocrine monotherapy in reducing the risks of disease recurrence and death—not only in older patients overall, but also in frail individuals with an ECOG performance status of 2 or higher. Particular emphasis is placed on the safety profile of ribociclib, with special attention to adverse events of special interest that demand enhanced monitoring throughout treatment. The phase 4 RibOB clinical trial has, for the first time, shown that three months of combination endocrine therapy with ribociclib modulates the immune system in elderly patients, potentially correcting age-related immunodeficiency by expanding the population of naïve T and B cells while reducing the memory cell compartment. A dedicated section examines two independent FDA pooled analyses evaluating the efficacy and safety of combination endocrine therapy in older adults (aged ≥70 years and ≥75 years) enrolled in three major randomized trials (PALOMA-2, MONALEESA-2, and MONARCH-3). This is complemented by a detailed review of cardiovascular toxicity associated with CDK4/6 inhibitors, as reported to the FDA Adverse Event Reporting System in routine clinical practice. The review also addresses clinically relevant drug–drug interactions that warrant careful consideration during CDK4/6 inhibitor therapy, and provides a practical clinical algorithm for managing concomitant use of CYP3A4 inhibitors or inducers when such co-administration becomes necessary.
- 10 August 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (4)
Ribociclib-based combination endocrine therapy in elderly and frail patients: key issues of efficacy, safety, and drug interactions requiring the attention of an oncologist
This review presents the findings of the most consequential large-scale randomized controlled trials and real-world practice studies on combination endocrine therapy with ribociclib in elderly patients with advanced HR-positive, HER2-negative breast cancer. Phase 3 and 3b randomized clinical trials (MONALEESA-2, MONALEESA-3, and CompLEEment-1) have consistently demonstrated that endocrine therapy combined with ribociclib confers a significant advantage over endocrine monotherapy in reducing the risks of disease recurrence and death—not only in older patients overall, but also in frail individuals with an ECOG performance status of 2 or higher. Particular emphasis is placed on the safety profile of ribociclib, with special attention to adverse events of special interest that demand enhanced monitoring throughout treatment. The phase 4 RibOB clinical trial has, for the first time, shown that three months of combination endocrine therapy with ribociclib modulates the immune system in elderly patients, potentially correcting age-related immunodeficiency by expanding the population of naïve T and B cells while reducing the memory cell compartment. A dedicated section examines two independent FDA pooled analyses evaluating the efficacy and safety of combination endocrine therapy in older adults (aged ≥70 years and ≥75 years) enrolled in three major randomized trials (PALOMA-2, MONALEESA-2, and MONARCH-3). This is complemented by a detailed review of cardiovascular toxicity associated with CDK4/6 inhibitors, as reported to the FDA Adverse Event Reporting System in routine clinical practice. The review also addresses clinically relevant drug–drug interactions that warrant careful consideration during CDK4/6 inhibitor therapy, and provides a practical clinical algorithm for managing concomitant use of CYP3A4 inhibitors or inducers when such co-administration becomes necessary.
- Open Access
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 106-119
The principle of "discretion" and its application in oncology during surgical treatment in accordance with clinical guidelines: law enforcement practice
Background. This article presents a thorough medical and legal examination of the principle of "discretion" in the surgical management of malignancies. The significance of this study arises from the mandatory implementation of clinical guidelines effective January 1, 2022, in accordance with Article 37 of Federal Law No. 323-ФЗ. This legislation has notably restricted the scope for individualized medical decision-making. At the same time, the complete algorithmization of surgical oncology remains fundamentally impossible due to the unique features of each clinical case. The authors interpret medical discretion as a specific form of administrative discretion – a legally conferred right enabling physicians to make informed and independent decisions based on clinical circumstances, evidence-based data, and the overarching principle of safeguarding the patient's health. Aim. To provide a comprehensive medical and legal analysis of the "discretion" principle within the surgical phase of cancer treatment, including examining its legal boundaries, its relationship with clinical guidelines, and the notion of informed voluntary consent, as well as an assessment of relevant law enforcement practices. Materials and methods. The study used system analysis, formal legal analysis, comparative law, and content analysis of judicial rulings. A total of 87 judicial decisions about civil cases from 2018 to 2025, relevant regulatory frameworks, and clinical guidelines issued by the Ministry of Health of Russia, the Association of Oncologists of Russia, the Russian Society of Clinical Oncology (RUSSCO), as well as NCCN and ESMO guidelines, along with the 8th edition of the TNM classification of malignant tumors, were reviewed. Results. The findings indicate that discrepancies in clinical and pathomorphological staging, which may reach up to 23.9% in colorectal cancer, render intraoperative approach adjustments a necessary practice. Analysis of specific court cases revealed that the legitimacy of extending the surgical intervention is evaluated not by the outcome but by the appropriateness of the surgeon's actions at the time they were performed, based on the intrinsic connection between surgical practices and pathological morphology, thereby facilitating a clear distinction in responsibility between surgery and pathology teams. Particular importance is attached to informed voluntary consent; it is the substance and completeness of this consent – rather than the mere availability of the document itself – that serves as the decisive mechanism for risk allocation. Conclusion. The authors establish criteria for the legality of extending the surgical intervention and advocate for enhancements to clinical guidelines, the format of informed voluntary consent, surgical protocols, the introduction of a standard for the "reasonable surgeon," and the legislative endorsement of the concept of "reasonable medical risk."
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 106-119
Open AccessThe principle of "discretion" and its application in oncology during surgical treatment in accordance with clinical guidelines: law enforcement practice
Background. This article presents a thorough medical and legal examination of the principle of "discretion" in the surgical management of malignancies. The significance of this study arises from the mandatory implementation of clinical guidelines effective January 1, 2022, in accordance with Article 37 of Federal Law No. 323-ФЗ. This legislation has notably restricted the scope for individualized medical decision-making. At the same time, the complete algorithmization of surgical oncology remains fundamentally impossible due to the unique features of each clinical case. The authors interpret medical discretion as a specific form of administrative discretion – a legally conferred right enabling physicians to make informed and independent decisions based on clinical circumstances, evidence-based data, and the overarching principle of safeguarding the patient's health. Aim. To provide a comprehensive medical and legal analysis of the "discretion" principle within the surgical phase of cancer treatment, including examining its legal boundaries, its relationship with clinical guidelines, and the notion of informed voluntary consent, as well as an assessment of relevant law enforcement practices. Materials and methods. The study used system analysis, formal legal analysis, comparative law, and content analysis of judicial rulings. A total of 87 judicial decisions about civil cases from 2018 to 2025, relevant regulatory frameworks, and clinical guidelines issued by the Ministry of Health of Russia, the Association of Oncologists of Russia, the Russian Society of Clinical Oncology (RUSSCO), as well as NCCN and ESMO guidelines, along with the 8th edition of the TNM classification of malignant tumors, were reviewed. Results. The findings indicate that discrepancies in clinical and pathomorphological staging, which may reach up to 23.9% in colorectal cancer, render intraoperative approach adjustments a necessary practice. Analysis of specific court cases revealed that the legitimacy of extending the surgical intervention is evaluated not by the outcome but by the appropriateness of the surgeon's actions at the time they were performed, based on the intrinsic connection between surgical practices and pathological morphology, thereby facilitating a clear distinction in responsibility between surgery and pathology teams. Particular importance is attached to informed voluntary consent; it is the substance and completeness of this consent – rather than the mere availability of the document itself – that serves as the decisive mechanism for risk allocation. Conclusion. The authors establish criteria for the legality of extending the surgical intervention and advocate for enhancements to clinical guidelines, the format of informed voluntary consent, surgical protocols, the introduction of a standard for the "reasonable surgeon," and the legislative endorsement of the concept of "reasonable medical risk."
- Open Access
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 134-139
Dynamics of morphological and immunohistochemical parameters during preoperative hormone sensitivity testing in patients with luminal HER2-negative breast cancer
Background. Breast cancer (BC) is a heterogeneous disease that presents significant challenges in treatment planning. A short-term preoperative test for hormone sensitivity (THS) is one approach to personalizing adjuvant systemic therapy for patients with BC. Despite its availability for over 25 years, several unresolved issues continue to limit the widespread adoption of test hormone therapy in clinical practice. Aim. To evaluate changes in morphological and immunohistochemical parameters during preoperative THS in patients with luminal HER2-negative BC and to identify factors influencing these changes. Materials and methods. The study cohort comprised 254 patients with luminal HER2-negative BC treated at the Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology between 2018 and 2024. During the preoperative stage, core biopsies of breast tumors were obtained, followed by administration of short-term THS. Premenopausal patients received tamoxifen with or without ovarian suppression using goserelin, while postmenopausal patients received aromatase inhibitors. Post-surgical assessment included evaluation of changes in tumor proliferative activity, as measured by degree of malignancy (G) and Ki67 levels, as well as changes in estrogen receptor (ER) and progesterone receptor (PR) expression in surgical specimens. Results. Following short-term THS, a statistically significant decrease was observed in the expression of ER (p0.001), PR (p0.001), Ki67 (p0.001), and degree of malignancy (p=0.031). Multivariate regression analysis identified baseline Ki67 (p0.001), drug type (p=0.012), and ER expression (p=0.012) as significant predictors of Ki67 reduction. Conclusion. Alterations in hormone receptor expression, Ki67, and degree of malignancy during preoperative THS facilitate prediction of clinical response and assessment of endocrine therapy effectiveness in vivo within a short timeframe. This approach may allow some patients to avoid unnecessary and highly toxic chemotherapy.
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 134-139
Open AccessDynamics of morphological and immunohistochemical parameters during preoperative hormone sensitivity testing in patients with luminal HER2-negative breast cancer
Background. Breast cancer (BC) is a heterogeneous disease that presents significant challenges in treatment planning. A short-term preoperative test for hormone sensitivity (THS) is one approach to personalizing adjuvant systemic therapy for patients with BC. Despite its availability for over 25 years, several unresolved issues continue to limit the widespread adoption of test hormone therapy in clinical practice. Aim. To evaluate changes in morphological and immunohistochemical parameters during preoperative THS in patients with luminal HER2-negative BC and to identify factors influencing these changes. Materials and methods. The study cohort comprised 254 patients with luminal HER2-negative BC treated at the Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology between 2018 and 2024. During the preoperative stage, core biopsies of breast tumors were obtained, followed by administration of short-term THS. Premenopausal patients received tamoxifen with or without ovarian suppression using goserelin, while postmenopausal patients received aromatase inhibitors. Post-surgical assessment included evaluation of changes in tumor proliferative activity, as measured by degree of malignancy (G) and Ki67 levels, as well as changes in estrogen receptor (ER) and progesterone receptor (PR) expression in surgical specimens. Results. Following short-term THS, a statistically significant decrease was observed in the expression of ER (p0.001), PR (p0.001), Ki67 (p0.001), and degree of malignancy (p=0.031). Multivariate regression analysis identified baseline Ki67 (p0.001), drug type (p=0.012), and ER expression (p=0.012) as significant predictors of Ki67 reduction. Conclusion. Alterations in hormone receptor expression, Ki67, and degree of malignancy during preoperative THS facilitate prediction of clinical response and assessment of endocrine therapy effectiveness in vivo within a short timeframe. This approach may allow some patients to avoid unnecessary and highly toxic chemotherapy.
- Open Access
- 3 July 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (3)
2nd Saint Petersburg International Consensus on the Diagnosis and Treatment of Breast Cancer «White Nights 2025»
В данной публикации представлены результаты II Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2025», который продолжает традицию углубленного обсуждения актуальных и спорных вопросов, возникающих в клинической практике. Под председательством члена-корреспондента РАН, профессора Владимира Федоровича Семиглазова в консенсусе приняли участие ведущие эксперты в области диагностики, хирургии, лучевой терапии и системного лечения рака молочной железы. Эксперты обсудили и проголосовали по 60 ключевым вопросам, касающимся как ранних стадий заболевания, так и метастатического рака молочной железы. Результаты консенсуса обеспечат необходимую основу для дальнейшего совершенствования клинической практики и разработки рекомендаций, направленных на улучшение лечения и качества жизни пациентов с данным заболеванием. Проведение III Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2026» запланировано на 4 июля 2026 г.
- 3 July 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (3)
Open Access2nd Saint Petersburg International Consensus on the Diagnosis and Treatment of Breast Cancer «White Nights 2025»
В данной публикации представлены результаты II Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2025», который продолжает традицию углубленного обсуждения актуальных и спорных вопросов, возникающих в клинической практике. Под председательством члена-корреспондента РАН, профессора Владимира Федоровича Семиглазова в консенсусе приняли участие ведущие эксперты в области диагностики, хирургии, лучевой терапии и системного лечения рака молочной железы. Эксперты обсудили и проголосовали по 60 ключевым вопросам, касающимся как ранних стадий заболевания, так и метастатического рака молочной железы. Результаты консенсуса обеспечат необходимую основу для дальнейшего совершенствования клинической практики и разработки рекомендаций, направленных на улучшение лечения и качества жизни пациентов с данным заболеванием. Проведение III Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2026» запланировано на 4 июля 2026 г.
- Open Access
- 3 July 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (3)
Navigated Targeted Axillary Dissection (NAVI-TAD) for Node-Positive to Node-Negative (cN1→ycN0) Conversion in Early-Stage Breast Cancer: Technical Description and Initial Results
Введение. Благодаря современным режимам неоадъювантной лекарственной терапии (НЛТ) у значимого числа пациентов с агрессивными подтипами раннего рака молочной железы (РМЖ) удается добиться полного патоморфологического ответа не только в первичной опухоли, но и в лимфатических узлах, что делает актуальным возможность деэскалации регионарной хирургии. Цель. Разработать технологию навигационной таргетной аксиллярной диссекции (NAVI-TAD) и оценить ее эффективность у больных ранним РМЖ с конверсией статуса лимфатических узлов cN(+) → ycN(-). Материалы и методы. В данное проспективное исследование включены 30 больных c ранним РМЖ со стадиями сT1–3N1М0, с наличием верифицированного опухолевого поражения одного-двух аксиллярных лимфатических узлов, с конверсией статуса лимфатических узлов cN1→ yсN0 после НЛТ, которым выполнена радикальная операция с проведением NAVI-TAD. Перед операцией под ультразвуковым контролем проводилась разметка таргетного лимфатического узла (с установленным титановым маркером до начала НЛТ) путем инъекции в паранодальную клетчатку 0,4 мл р-ра индигокармина 4 мг/мл с «трассировкой» раствора по ходу введения для поиска лимфатического узла во время операции. Детекция сигнальных лимфатических узлов (СЛУ) выполнялась радиоактивным методом (технеций-99m); проведено сопоставление СЛУ и таргетных лимфатических узлов. В удаленных лимфатических узлах проводили поиск маркированного лимфатического узла и резидуальной опухолевой ткани при срочном рентгенологическом и гистологическом исследованиях. Результаты. В 29 из 30 случаев (96,7 %) технология NAVI-TAD оказалась успешной: число удаленных лимфатических узлов в среднем не превышало трех, что позволило уже на этапе срочного гистологического исследования подтвердить наличие полного регресса опухоли у 43,3 % больных, а у пациенток с наличием резидуального опухолевого поражения лимфатических узлов сразу расширить объем регионарной хирургии. Биопсия сигнальных лимфатических узлов (БСЛУ) успешно проведена у 83,3 % больных; в пяти случаях не удалось идентифицировать СЛУ ввиду отсутствия радиоактивного сигнала от них; при этом у четырех из пяти данных пациенток применяемая технология позволила обнаружить таргетные лимфатические узлы и оценить наличие резидуального опухолевого поражения. При сопоставлении технологии NAVI-TAD и БСЛУ в 20 % случаев таргетные лимфатические узлы не являлись сигнальными, что имело решающее значение для эскалации лекарственного лечения и назначения постнеоадъювантной терапии. Заключение. Технология NAVI-TAD является безопасной и высокоинформативной альтернативой рутинной аксиллярной лимфодиссекции у пациенток с исходным поражением лимфатических узлов (cN+) после неоадъювантной лекарственной терапии.
- 3 July 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (3)
Open AccessNavigated Targeted Axillary Dissection (NAVI-TAD) for Node-Positive to Node-Negative (cN1→ycN0) Conversion in Early-Stage Breast Cancer: Technical Description and Initial Results
Введение. Благодаря современным режимам неоадъювантной лекарственной терапии (НЛТ) у значимого числа пациентов с агрессивными подтипами раннего рака молочной железы (РМЖ) удается добиться полного патоморфологического ответа не только в первичной опухоли, но и в лимфатических узлах, что делает актуальным возможность деэскалации регионарной хирургии. Цель. Разработать технологию навигационной таргетной аксиллярной диссекции (NAVI-TAD) и оценить ее эффективность у больных ранним РМЖ с конверсией статуса лимфатических узлов cN(+) → ycN(-). Материалы и методы. В данное проспективное исследование включены 30 больных c ранним РМЖ со стадиями сT1–3N1М0, с наличием верифицированного опухолевого поражения одного-двух аксиллярных лимфатических узлов, с конверсией статуса лимфатических узлов cN1→ yсN0 после НЛТ, которым выполнена радикальная операция с проведением NAVI-TAD. Перед операцией под ультразвуковым контролем проводилась разметка таргетного лимфатического узла (с установленным титановым маркером до начала НЛТ) путем инъекции в паранодальную клетчатку 0,4 мл р-ра индигокармина 4 мг/мл с «трассировкой» раствора по ходу введения для поиска лимфатического узла во время операции. Детекция сигнальных лимфатических узлов (СЛУ) выполнялась радиоактивным методом (технеций-99m); проведено сопоставление СЛУ и таргетных лимфатических узлов. В удаленных лимфатических узлах проводили поиск маркированного лимфатического узла и резидуальной опухолевой ткани при срочном рентгенологическом и гистологическом исследованиях. Результаты. В 29 из 30 случаев (96,7 %) технология NAVI-TAD оказалась успешной: число удаленных лимфатических узлов в среднем не превышало трех, что позволило уже на этапе срочного гистологического исследования подтвердить наличие полного регресса опухоли у 43,3 % больных, а у пациенток с наличием резидуального опухолевого поражения лимфатических узлов сразу расширить объем регионарной хирургии. Биопсия сигнальных лимфатических узлов (БСЛУ) успешно проведена у 83,3 % больных; в пяти случаях не удалось идентифицировать СЛУ ввиду отсутствия радиоактивного сигнала от них; при этом у четырех из пяти данных пациенток применяемая технология позволила обнаружить таргетные лимфатические узлы и оценить наличие резидуального опухолевого поражения. При сопоставлении технологии NAVI-TAD и БСЛУ в 20 % случаев таргетные лимфатические узлы не являлись сигнальными, что имело решающее значение для эскалации лекарственного лечения и назначения постнеоадъювантной терапии. Заключение. Технология NAVI-TAD является безопасной и высокоинформативной альтернативой рутинной аксиллярной лимфодиссекции у пациенток с исходным поражением лимфатических узлов (cN+) после неоадъювантной лекарственной терапии.
- 30 March 2026
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 1
Contrast-enhanced ultrasound examination of invasive breast cancer: opportunities for determining the molecular subtype and predicting axillary metastasis
Contrast-enhanced ultrasound examination expands the opportunities of multiparametric ultrasound examination due to functional assessment of tumour microcirculation and angioarchitecture. The molecular biological subtypes of breast cancer differ in biology and clinical progression, which is potentially reflected in the dynamics of perfusion during contrast-enhanced ultrasound. The search for ultrasound markers that can predict the phenotype of the tumor and the risk of metastasis to the axillary lymph nodes prior to a tumor biopsy is of practical importance for personalization, routing and treatment. However, there is still insufficient data on reproducible signs of contrasting in different phenotypes and degrees of malignancy. The aim of the study was to evaluate the diagnostic informative value of qualitative and quantitative ultrasound contrast parameters in the differential diagnosis of molecular subtypes of breast cancer and the degree of tumor differentiation, as well as in predicting metastatic lesions of the axillary lymph nodes. Materials and methods. The prospective single-center study included 76 patients with invasive primary operable breast cancer (stage I–IIIa) between May and September 2024. Ultrasound examination was performed in B-mode and color Doppler mapping mode, followed by contrast-enhanced ultrasound examination (intravenous bolus injection of sulfur hexafluoride (SonoVue, 2.4 ml)). Qualitative signs (homogeneity, gain intensity, wash-in/wash-out, contours, perfusion defects, etc.) and quantitative parameters (TTP, PI, AS, DS) were analyzed. Postoperative histological and immunohistochemical data were considered as reference ones; Fischer test, Mann-Whitney U–test, logistic regression and ROC analysis were applied. Results. Luminal subtypes prevailed in the general cohort (90.6%); metastases to axillary lymph nodes were detected in 25% of cases. The most common contrast patterns were heterogeneous gain (79%), hyperintensive accumulation (85.7%), rapid wash-in (78.6%) and accelerated wash-out (73.8%). In terms of quantitative parameters, tumors with a non–luminal phenotype were characterized by a shorter time to peak (TTP: 6.5 s, in luminal subtypes – 9.9 s; p < 0.05); tumors of the non-luminal HER2+ subtype demonstrated the most "dynamic" perfusion curves and a more pronounced wash-out (DS is statistically lower compared to luminal ones; p < 0.05). There was no significant relationship between the parameters of contrast ultrasound examination and the degree of malignancy (G1–2 vs G3) in the presence of trends towards greater heterogeneity in less differentiated tumors. For the prognosis of axillary metastasis, an association of "absence of rapid wash-in" with the presence of metastases in axillary lymph nodes (OR 4.7; 95% CI 1.5–14.8; p = 0.006), as well as an increase in TTP in patients with metastases (11.85 s / 9.89 s; p < 0.05) was revealed; the diagnostic effectiveness of TTP was moderate (AUC ≈0.66; sensitivity 68%, specificity 59%). Conclusions. The technique of ultrasound examination using an echocontrast preparation makes it possible to identify differences in perfusion characteristics of breast cancer depending on its molecular subtype: non-luminal HER2+ tumors have a more aggressive wash-in/wash-out profile, and triple negative cancer more often demonstrates a peripheral type of contrasting with delayed centralization. Luminal subtypes occupy an intermediate position and are worse differentiated by the isolated parameters of ultrasound contrast, which justifies the need for an integrated approach. The wash-in and TTP parameters can serve as additional markers for predicting axillary lymph node damage, but their predictive accuracy is limited and requires confirmation in more subtype-balanced samples.
- 30 March 2026
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 1
Contrast-enhanced ultrasound examination of invasive breast cancer: opportunities for determining the molecular subtype and predicting axillary metastasis
Contrast-enhanced ultrasound examination expands the opportunities of multiparametric ultrasound examination due to functional assessment of tumour microcirculation and angioarchitecture. The molecular biological subtypes of breast cancer differ in biology and clinical progression, which is potentially reflected in the dynamics of perfusion during contrast-enhanced ultrasound. The search for ultrasound markers that can predict the phenotype of the tumor and the risk of metastasis to the axillary lymph nodes prior to a tumor biopsy is of practical importance for personalization, routing and treatment. However, there is still insufficient data on reproducible signs of contrasting in different phenotypes and degrees of malignancy. The aim of the study was to evaluate the diagnostic informative value of qualitative and quantitative ultrasound contrast parameters in the differential diagnosis of molecular subtypes of breast cancer and the degree of tumor differentiation, as well as in predicting metastatic lesions of the axillary lymph nodes. Materials and methods. The prospective single-center study included 76 patients with invasive primary operable breast cancer (stage I–IIIa) between May and September 2024. Ultrasound examination was performed in B-mode and color Doppler mapping mode, followed by contrast-enhanced ultrasound examination (intravenous bolus injection of sulfur hexafluoride (SonoVue, 2.4 ml)). Qualitative signs (homogeneity, gain intensity, wash-in/wash-out, contours, perfusion defects, etc.) and quantitative parameters (TTP, PI, AS, DS) were analyzed. Postoperative histological and immunohistochemical data were considered as reference ones; Fischer test, Mann-Whitney U–test, logistic regression and ROC analysis were applied. Results. Luminal subtypes prevailed in the general cohort (90.6%); metastases to axillary lymph nodes were detected in 25% of cases. The most common contrast patterns were heterogeneous gain (79%), hyperintensive accumulation (85.7%), rapid wash-in (78.6%) and accelerated wash-out (73.8%). In terms of quantitative parameters, tumors with a non–luminal phenotype were characterized by a shorter time to peak (TTP: 6.5 s, in luminal subtypes – 9.9 s; p < 0.05); tumors of the non-luminal HER2+ subtype demonstrated the most "dynamic" perfusion curves and a more pronounced wash-out (DS is statistically lower compared to luminal ones; p < 0.05). There was no significant relationship between the parameters of contrast ultrasound examination and the degree of malignancy (G1–2 vs G3) in the presence of trends towards greater heterogeneity in less differentiated tumors. For the prognosis of axillary metastasis, an association of "absence of rapid wash-in" with the presence of metastases in axillary lymph nodes (OR 4.7; 95% CI 1.5–14.8; p = 0.006), as well as an increase in TTP in patients with metastases (11.85 s / 9.89 s; p < 0.05) was revealed; the diagnostic effectiveness of TTP was moderate (AUC ≈0.66; sensitivity 68%, specificity 59%). Conclusions. The technique of ultrasound examination using an echocontrast preparation makes it possible to identify differences in perfusion characteristics of breast cancer depending on its molecular subtype: non-luminal HER2+ tumors have a more aggressive wash-in/wash-out profile, and triple negative cancer more often demonstrates a peripheral type of contrasting with delayed centralization. Luminal subtypes occupy an intermediate position and are worse differentiated by the isolated parameters of ultrasound contrast, which justifies the need for an integrated approach. The wash-in and TTP parameters can serve as additional markers for predicting axillary lymph node damage, but their predictive accuracy is limited and requires confirmation in more subtype-balanced samples.
- Open Access
- 28 March 2026
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 30 (1) , 68-80
The potential of multiparametric contrast-enhanced ultrasound to detect and predict sentinel lymph node status in invasive breast cancer
Axillary mapping and assessment of axillary lymph node status remains a key staging issue for determining treatment strategies and algorithms for patients with invasive breast cancer. Various ultrasound techniques (elastography, color Doppler, and SMI) are used to improve diagnostic accuracy. In recent years, ultrasound contrast agents have been widely adopted, increasing the diagnostic capabilities of ultrasound. The aim: to evaluate the diagnostic efficiency of CEUS and multiparametric ultrasound with the inclusion of the ultrasound contrast technique in preoperative detection and prediction of metastases in the SLN. Materials and methods. This study included a comprehensive analysis of data from 120 up-front patients with invasive breast cancer to evaluate the diagnostic value of qualitative (contrast patterns), quantitative, combined and multiparametric (combined CEUS parameters + B-mode) models. Results. Axillary lymph node metastases were detected in 29.2% of cases; the proportion of pN+ patients increased from patterns I–II to IV–V (up to 71–100%; p p < 0.001; AUC 0.84), transverse size and blood flow type in the color Doppler imaging mode had moderate information content ( p = 0.02 and p = 0.077, respectively). Integration of features improved accuracy: combined model – AUC 0.686, sensitivity – 60%, specificity – 81.2%, and multiparametric (combined with the addition of B-mode and color Doppler imaging) – the highest values (AUC 0.78; sensitivity 65.8%, specificity 80%). Conclusion. Intradermal paraareolar ultrasound injection of contrast agent provides a high rate of lymph node (SLN) identification and predict the status and metastatic burden of axillary lymph nodes. Multiparametric ultrasound, combining B-mode, color Doppler, and CEUS improves the diagnostic accuracy of axillary staging in patients with breast cancer.
- 28 March 2026
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 30 (1) , 68-80
Open AccessThe potential of multiparametric contrast-enhanced ultrasound to detect and predict sentinel lymph node status in invasive breast cancer
Axillary mapping and assessment of axillary lymph node status remains a key staging issue for determining treatment strategies and algorithms for patients with invasive breast cancer. Various ultrasound techniques (elastography, color Doppler, and SMI) are used to improve diagnostic accuracy. In recent years, ultrasound contrast agents have been widely adopted, increasing the diagnostic capabilities of ultrasound. The aim: to evaluate the diagnostic efficiency of CEUS and multiparametric ultrasound with the inclusion of the ultrasound contrast technique in preoperative detection and prediction of metastases in the SLN. Materials and methods. This study included a comprehensive analysis of data from 120 up-front patients with invasive breast cancer to evaluate the diagnostic value of qualitative (contrast patterns), quantitative, combined and multiparametric (combined CEUS parameters + B-mode) models. Results. Axillary lymph node metastases were detected in 29.2% of cases; the proportion of pN+ patients increased from patterns I–II to IV–V (up to 71–100%; p p < 0.001; AUC 0.84), transverse size and blood flow type in the color Doppler imaging mode had moderate information content ( p = 0.02 and p = 0.077, respectively). Integration of features improved accuracy: combined model – AUC 0.686, sensitivity – 60%, specificity – 81.2%, and multiparametric (combined with the addition of B-mode and color Doppler imaging) – the highest values (AUC 0.78; sensitivity 65.8%, specificity 80%). Conclusion. Intradermal paraareolar ultrasound injection of contrast agent provides a high rate of lymph node (SLN) identification and predict the status and metastatic burden of axillary lymph nodes. Multiparametric ultrasound, combining B-mode, color Doppler, and CEUS improves the diagnostic accuracy of axillary staging in patients with breast cancer.
- Open Access
- 11 February 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (4) , 326-330
Evaluation of ctDNA during primary treatment of patients with triple-negative breast cancer: scientific novelty and clinical prospects. Case report
Triple-negative breast cancer (TNBC) is the most unfavorable subtype of breast cancer. Achieving pathological complete responce (pCR) is an important prognostic factor in patients diagnosed with TNBC, as it is associated with increased overall and disease-free survival. Currently, clinical parameters and pathological examination of resection tissue after surgery are used to evaluate the effectiveness of neoadjuvant drug chemotherapy (NAC). Traditional clinical and instrumental methods used in routine practice (examination, palpation, ultrasound of the mammary glands and regional areas, mammography, and MRI of the mammary glands) often do not allow for an accurate assessment of the treatment effect. The rate of detection of complete responses may be lower with clinical and instrumental assessment of the effect compared to pathological examination. In this regard, there is growing interest in assessing the effect of NAC based on changes in circulating tumor DNA (ctDNA) levels in the blood, which is characterized by the presence of genetic alterations specific to tumor tissue, i.e., liquid biopsy. This study examines two clinical cases of TNBC, determining the dynamics of ctDNA level changes during treatment and comparing these results with the severity of pathological tumor responce after NAC. In one case, pathological complete responce was achieved, while in the second, significant residual tumor was detected. Mutations for tracking ctDNA level dynamics were selected based on bioinformatics analysis of whole-exome sequencing of tumor biopsy samples and patient’s blood. Plasma ctDNA levels were assessed using digital PCR (dPCR). We obtained quantitative results for ctDNA determination in the plasma of patients with TNBC at five points and compared the dynamics of ctDNA level changes with the results of NAC. The study discusses the possible relationship between the observed ctDNA dynamics and treatment response (achievement of complete pathological tumor regression) and the feasibility of using liquid biopsy in predicting tumor response to NAC.
- 11 February 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (4) , 326-330
Open AccessEvaluation of ctDNA during primary treatment of patients with triple-negative breast cancer: scientific novelty and clinical prospects. Case report
Triple-negative breast cancer (TNBC) is the most unfavorable subtype of breast cancer. Achieving pathological complete responce (pCR) is an important prognostic factor in patients diagnosed with TNBC, as it is associated with increased overall and disease-free survival. Currently, clinical parameters and pathological examination of resection tissue after surgery are used to evaluate the effectiveness of neoadjuvant drug chemotherapy (NAC). Traditional clinical and instrumental methods used in routine practice (examination, palpation, ultrasound of the mammary glands and regional areas, mammography, and MRI of the mammary glands) often do not allow for an accurate assessment of the treatment effect. The rate of detection of complete responses may be lower with clinical and instrumental assessment of the effect compared to pathological examination. In this regard, there is growing interest in assessing the effect of NAC based on changes in circulating tumor DNA (ctDNA) levels in the blood, which is characterized by the presence of genetic alterations specific to tumor tissue, i.e., liquid biopsy. This study examines two clinical cases of TNBC, determining the dynamics of ctDNA level changes during treatment and comparing these results with the severity of pathological tumor responce after NAC. In one case, pathological complete responce was achieved, while in the second, significant residual tumor was detected. Mutations for tracking ctDNA level dynamics were selected based on bioinformatics analysis of whole-exome sequencing of tumor biopsy samples and patient’s blood. Plasma ctDNA levels were assessed using digital PCR (dPCR). We obtained quantitative results for ctDNA determination in the plasma of patients with TNBC at five points and compared the dynamics of ctDNA level changes with the results of NAC. The study discusses the possible relationship between the observed ctDNA dynamics and treatment response (achievement of complete pathological tumor regression) and the feasibility of using liquid biopsy in predicting tumor response to NAC.
- Open Access
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 71-84
From clinical trials to routine practice: 7-year results of the monarchE randomized clinical trial and experience with the use of abemaciclib in hormone-dependent, HER2-negative, high-risk, early breast cancer
The 7-year results of the monarchE randomized clinical trial of adjuvant endocrine therapy escalation with abemaciclib in patients with hormone-dependent, HER2-negative, high-risk, early breast cancer. Three-year experience with the use of abemaciclib in 64 patients with hormone-dependent, HER2-negative, early breast cancer in real-world practice is analyzed, and the criteria for selecting combination endocrine therapy and the safety profile of treatment escalation are assessed. An indirect comparison of data from the Russian analysis and the randomized clinical monarchE trial of adjuvant endocrine therapy escalation in patients with a high risk of recurrence is conducted. Clinical cases of abemaciclib use in routine practice in Russian patients are presented.
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 71-84
Open AccessFrom clinical trials to routine practice: 7-year results of the monarchE randomized clinical trial and experience with the use of abemaciclib in hormone-dependent, HER2-negative, high-risk, early breast cancer
The 7-year results of the monarchE randomized clinical trial of adjuvant endocrine therapy escalation with abemaciclib in patients with hormone-dependent, HER2-negative, high-risk, early breast cancer. Three-year experience with the use of abemaciclib in 64 patients with hormone-dependent, HER2-negative, early breast cancer in real-world practice is analyzed, and the criteria for selecting combination endocrine therapy and the safety profile of treatment escalation are assessed. An indirect comparison of data from the Russian analysis and the randomized clinical monarchE trial of adjuvant endocrine therapy escalation in patients with a high risk of recurrence is conducted. Clinical cases of abemaciclib use in routine practice in Russian patients are presented.
- 28 December 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 47 (4)
Evaluation of the clinical and economic feasibility of the use of certain adjuvant therapies in breast cancer treatment
Objective. To assess the clinical and economic feasibility of using CDK4/6 inhibitors (abemaciclib, ribociclib) in adjuvant therapy of luminal HER2-negative breast cancer (BC). Material and methods. Socio-economic consequences of CDK4/6 inhibitors (abemaciclib and ribociclib) application in adjuvant therapy regimes in patients with HR+HER2-negative BC were evaluated. The analysis included patients with affected lymph nodes, similar in their characteristics to patients from the MonarchE randomized clinical trial (RCT) and patients with N1—3 status of the lymph nodes from the NATALEE RCT. Mathematical modeling was used to evaluate the clinical efficacy of adjuvant endocrine therapy (ET) with CDK4/6 inhibitor and without it in a hypothetical cohort of 1000 people within 5 and 10 years based on a calculated risk of recurrence and death. Direct medical costs for adjuvant therapy, drug treatment of metastatic BC in case of the disease progression, indirect (supplementary) costs associated with loss of gross domestic product (GDP) due to disability, as well as the value of the incremental cost-effectiveness ratio and the return on investment indicator per 1 invested rouble were predicted. Results. The use of CDK4/6 inhibitors (abemaciclib and ribociclib) in regimens of ET of HR+HER2-negative BC with affected lymph nodes leads to a statistically significant threat of adverse events (death or progression) compared to ET (threat ratio 0.70 (95% CI 0.64; 0.77). Based on a hypothetical cohort of 1000 patients, the decrease in the number of adverse events over 5 and 10 years would be 53 (27.9%) and 89 (25.7%) events, respectively. The estimated costs of CDK4/6 inhibitors application are significantly higher than that of standard adjuvant ET. However, considering the reduced risk of progression of the disease in presence of the therapy with abemaciclib and ribociclib, lower costs for treatment of the progressive disease — metastatic BC — for the population of patients have been noted for 5 and 10 years by 35.0 and 36.8%, respectively. The return on investment indicators per 1 invested rouble, taking into account the avoided loss of GDP and lower costs for therapy at the stage of progression in the group of adjuvant therapy with CDK4/6 inhibitors were 0.14 RUB and 0.52 RUB excluding discount, 0.13 RUB and 0.36 RUB considering 5% discount on the 5- and 10-year modelling horizon, respectively. Conclusion. The use of CDK4/6 inhibitors (abemaciclib, ribociclib) in adjuvant therapy of luminal HER2-negative breast cancer may be clinically and economically feasible, thus the analysis results should be updated in the future taking into account the availability of data from ongoing clinical trials.
- 28 December 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 47 (4)
Evaluation of the clinical and economic feasibility of the use of certain adjuvant therapies in breast cancer treatment
Objective. To assess the clinical and economic feasibility of using CDK4/6 inhibitors (abemaciclib, ribociclib) in adjuvant therapy of luminal HER2-negative breast cancer (BC). Material and methods. Socio-economic consequences of CDK4/6 inhibitors (abemaciclib and ribociclib) application in adjuvant therapy regimes in patients with HR+HER2-negative BC were evaluated. The analysis included patients with affected lymph nodes, similar in their characteristics to patients from the MonarchE randomized clinical trial (RCT) and patients with N1—3 status of the lymph nodes from the NATALEE RCT. Mathematical modeling was used to evaluate the clinical efficacy of adjuvant endocrine therapy (ET) with CDK4/6 inhibitor and without it in a hypothetical cohort of 1000 people within 5 and 10 years based on a calculated risk of recurrence and death. Direct medical costs for adjuvant therapy, drug treatment of metastatic BC in case of the disease progression, indirect (supplementary) costs associated with loss of gross domestic product (GDP) due to disability, as well as the value of the incremental cost-effectiveness ratio and the return on investment indicator per 1 invested rouble were predicted. Results. The use of CDK4/6 inhibitors (abemaciclib and ribociclib) in regimens of ET of HR+HER2-negative BC with affected lymph nodes leads to a statistically significant threat of adverse events (death or progression) compared to ET (threat ratio 0.70 (95% CI 0.64; 0.77). Based on a hypothetical cohort of 1000 patients, the decrease in the number of adverse events over 5 and 10 years would be 53 (27.9%) and 89 (25.7%) events, respectively. The estimated costs of CDK4/6 inhibitors application are significantly higher than that of standard adjuvant ET. However, considering the reduced risk of progression of the disease in presence of the therapy with abemaciclib and ribociclib, lower costs for treatment of the progressive disease — metastatic BC — for the population of patients have been noted for 5 and 10 years by 35.0 and 36.8%, respectively. The return on investment indicators per 1 invested rouble, taking into account the avoided loss of GDP and lower costs for therapy at the stage of progression in the group of adjuvant therapy with CDK4/6 inhibitors were 0.14 RUB and 0.52 RUB excluding discount, 0.13 RUB and 0.36 RUB considering 5% discount on the 5- and 10-year modelling horizon, respectively. Conclusion. The use of CDK4/6 inhibitors (abemaciclib, ribociclib) in adjuvant therapy of luminal HER2-negative breast cancer may be clinically and economically feasible, thus the analysis results should be updated in the future taking into account the availability of data from ongoing clinical trials.